State of Play
We are experiencing a “golden twenties” in science with breakthrough therapies in rare diseases, oncology, cell and gene therapy, and regenerative medicine, but…
-
Biotech and Big Pharma will bring a record number of NCEs and biologics to market
-
Precision-medicine at the core
-
Drug development model essentially unchanged since 1960ies intro of RCTs and evidence-based medicine
-
Prices for new drugs keep going up
-
Combined budget impact will put pressure on government and private payers
Opportunity to re-purpose and improve established therapies with novel drug design and delivery systems
-
Improve established therapies with novel drug design and delivery systems
-
Re-purpose known drugs based on new science; design new patentable molecules and delivery systems
Opportunity to transform drug development leveraging digital solutions
-
Established biopharma is conservative and without incentives to cut development costs
-
Many tech companies, incl start-ups, have individually novel digital solutions but fail to evolve into a decentralised ecosystem
-
Patient-centricity still not at the centre of the biopharma development model